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Abstract
The cardiovascular system is affected by a wide range of path-
ological processes, including neoplastic, inflammatory, ische-
mic, and congenital aetiology. Magnetic resonance imaging
(MRI) and positron emission tomography (PET) are state-of-
the-art imaging modalities used in the evaluation of these car-
diovascular disorders. MRI has good spatial and temporal
resolutions, tissue characterization and multi-planar imaging/
reconstruction capabilities, which makes it useful in the eval-
uation of cardiac morphology, ventricular and valvar function,
disease characterization, and evaluation of myocardial viabil-
ity. FDG-PET provides valuable information on the metabolic
activity of the cardiovascular diseases, including ischemia,
inflammation, and neoplasm. MRI and FDG-PETcan provide
complementary information on the evaluation of several car-
diovascular disorders. For example, in cardiac masses, FDG-
PET provides the metabolic information for indeterminate
cardiac masses. MRI can be used for localizing and character-
izing abnormal hypermetabolic foci identified incidentally on
PET scan and also for local staging. A recent advance in im-
aging technology has been the development of integrated
PET/MRI systems that utilize the advantages of PET and
MRI in a single examination. The goal of this manuscript is
to provide a comprehensive review on the incremental value
of PET and MRI in the evaluation of cardiovascular diseases.
Main Messages
•MRI has good spatial and temporal resolutions, tissue char-
acterization, and multi-planar reconstruction
• FDG-PET provides valuable information on the metabolic
activity of cardiovascular disorders
• PET and MRI provide complementary information on the
evaluation of cardiovascular disorders
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Introduction
Cardiovascular disease (CVD), which includes ischemia, in-
flammation, neoplasia, and congenital disorders accounts for
30 % of all deaths and is a leading cause of morbidity and
mortality [1]. Early and accurate diagnosis is essential for the
optimal management of these disorders. Several imaging mo-
dalities are used in the evaluation of cardiovascular disorders,
each with their inherent advantages and disadvantages.
Echocardiography is a widely available and portable modality,
and there is good clinical familiarity with its application to
cardiovascular disease. However, echocardiography is strong-
ly operator-dependent, in some cases limited by acoustic win-
dow, and has limited tissue characterization [2]. Cardiac cath-
eterization is the gold standard for evaluation of coronary
vascular abnormalities and for interventional procedures.
Computed tomography (CT) is a noninvasive technique
which offers a three dimensional data set, is relatively operator
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independent, and provides good spatial resolution. Functional
information is typically not obtained, but can be obtained if
retrospective electrocardiographic (ECG)-gated acquisitions
are utilized, although they are associated with higher radiation
doses. Single-photon emission computed tomography
(SPECT) is widely used in the evaluation of myocardial is-
chemia. Magnetic resonance imaging (MRI) and positron
emission tomography (PET) are the two other commonly used
imaging modalities.
The combination of PET and MRI often provides incre-
mental information in the evaluation of cardiovascular dis-
eases, more than each of the individual modalities separately.
Based on our literature review, there is no comprehensive
review on the incremental role of PET and MRI in evaluation
of cardiovascular disorders, and therefore the goal of this man-
uscript is to provide one.
Magnetic resonance imaging
MRI has several advantages including good spatial resolution,
good temporal resolution, wide field-of-view, and multi-
planar imaging/reconstruction capabilities, all without using
ionizing radiation. In addition,MRI has tissue characterization
capabilities due to inherent soft-tissue contrast, which can be
brought out using different tissue-weighted sequences and
augmented by administration of gadolinium-based contrast
agents. MRI provides exquisite morphological information,
and in addition, ventricular and valvular function can be quan-
tified. There are numerous available MRI sequences that can
be selected for a tailored approach each clinical scenario.
(Table 1). Limitations of MRI include the cost, availability,
and long duration of scanning, as well as a relative paucity of
skilled readers and technologists. MRI cannot be used in pa-
tients with contraindications including those with metallic de-
vices and those with claustrophobia. MRI is also avoided in
patients with severe renal dysfunction due to the risk of
nephrogenic systemic fibrosis [3].
Positron emission tomography
PET is based on the beta decay of radioisotopes that result in
the emission of positron, a positively charged beta particle,
which travels for few millimetres after emission and then col-
lides with an electron resulting in annihilation of both and
subsequent formation of two high-energy (511 kev) gamma
rays. FDG (18F-fluoro-deoxy-glucose) is one of the most com-
mon PET isotopes, used for evaluating metabolism. In the
cardiovascular system, FDG is used in the evaluation of myo-
cardial viability, inflammatory/infectious disorders, neo-
plasms, and atherosclerosis. FDG-PET is very helpful for stag-
ing malignancies, optimizing biopsy location, guiding radia-
tion therapy, assessing tumour response to therapy, and detect-
ing tumour recurrence [4]. 11C acetate and 11C palmitate
provide insight into myocardial metabolism. Rubidium 82
chloride, 13-N ammonia, and 15O water are useful in the
assessment of myocardial perfusion [5, 6]. While PET has
limited spatial resolution and anatomical localization, this
can be overcome by adding CT (PET/CT), which also helps
in attenuation correction—however, it adds to the radiation
dose. Cardiac PET protocols and patient preparation are sum-
marized in Table 2 [5–8].
Cardiac PET and MRI
MRI and FDG-PET can provide complementary information
on the evaluation of several cardiovascular disorders. The ex-
quisite morphological information and tissue characterization
capabilities of MRI can be complementary to the metabolic
information of FDG-PET. The information obtained from
PET and MRI acquisitions can be interpreted separately or
can be fused using dedicated software algorithms. A signifi-
cant challenge in fusion is achieving both spatial and temporal
alignment, particularly in pulmonary and cardiac systems [9].
Cardiac motion can be improved by ECG-gating of both PET
and MRI, while respiratory motion requires navigator gating
for MRI or list mode for PET. Another challenge is the differ-
ence in acquisition times, which is 5–6 minutes for PET and
just a few seconds for each MRI sequence. Studies have
shown that fusion of PET and MRI can show misalignment
as much as 2.0±1.6 mm [10].
Hybrid PET/MRI
Dedicated hybrid PET/MR systems have been recently intro-
duced, which can potentially provide one-stop evaluation of
cardiovascular disorders. The three commercially available
PET/MR systems are (1) the Biograph mMR (Siemens
Healthcare, Erlangen, Germany) in which PET detectors are
integrated into the MR system with a single gantry using an
avalanche photodiode-based technology, which allows simul-
taneous acquisition of PET and MR data; (2) the Philips
Ingenuity TF PET/MR (Philips Healthcare, Andover, MA),
which has a sequential design with two gantries positioned
at each end of a single patient; and (3) the Discovery PET/
CT 690+Discovery MR 750 (GE Healthcare, Waukesha,
WI), in which the PET/CT and MRI scanners are located in
two adjacent rooms, and the patient is transferred between
these two rooms using a detachable table (11). The advantage
of these hybrid PET/MR systems is that they combine the
strengths of MRI, i.e. morphological details, tissue character-
ization and spatial resolution, with that of FDG-PET, i.e., met-
abolic information. Compared tomanual fusion, the integrated
PET/MR systems provide improved spatial and temporal
alignment. MRI image-based motion correction can also im-
prove artefacts such as motion and partial volume effect in
PET scanning. In addition, the hybrid technique results in
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significant time savings as compared with performing two
separate examinations, improves throughput, and also reduces
patient discomfort [9].
However, several challenges also exist in achieving wide-
spread acceptance of this novel technology. This includes hard-
ware issues such as photomultiplier tubes in the PET not work-
ing with strong magnetic fields, PET detectors producing mag-
netic field heterogeneities, and MRI surface coils causing un-
wanted attenuation interfering with gamma rays. Another im-
portant challenge is to develop a robust attenuation correction
technique to accurately quantify the standardized uptake values
(SUVs), since MRI signal does not contain information about
tissue attenuation but reflects the distribution of protons. MR
attenuation correction can be performed based on segmenta-
tion or atlas-based techniques. The segmentation approach is
based on co-registration of the MR images to the PET trans-
mission images using a surface matching technique, which is
then segmented into several different classes. Using either a
T1-weighted spoiled gradient echo, or T1-weighted 2-point
mDixon, or ultra-short TE sequence, a three-segment model
(air, soft tissue, lung) or a four-segment model (air, soft tissue,
fat, and lung) can be used [11, 12]. In the atlas-based approach,
an atlas is generated using a surplus of prior scans with corres-
ponding known attenuation corrections. Each individual scan
can be co-registered to the atlas by comparing each voxel to its
nearest neighbours in the atlas. Then, the attenuation coeffi-
cients can be interpolated from the generated atlas [12].
Applications of cardiac PET and MRI
In the following sections we will discuss the utility of PETand
MRI in specific clinical cardiovascular scenarios. In each sce-
nario, we will begin by discussing the current role of MRI and
PET individually in the evaluation of these diseases and fol-
low it up with the complementary information provided by
both, as well as integrated PET/MRI technology (Table 3).
Cardiac masses
Cardiac masses may be non-neoplastic (thrombus, hematoma,
lipomatous hypertrophy, pericardial cyst), benign neoplastic
(myxoma, f ib roe las toma, l ipoma, hemangioma,
paraganglioma, rhabdomyoma, fibroma), or malignant neo-
plastic (metastasis, sarcoma, lymphoma, leukemia, mesothe-
lioma). The most common cardiac mass is thrombus.
Secondary tumours are significantly more common than pri-
mary tumours [13]. Myxoma is the most common primary
tumour in the heart [14]. The role of imaging is (1) to charac-
terize the mass, since it determines treatment strategy; (2)
determine local staging, including extent of the tumour and
involvement of adjacent structures, which is essential for sur-
gical mapping; (3) to determine if chemo- or radiotherapy is
required along with surgery; and (4) to assess response to
therapy [15].
Table 1 MRI sequences and their utility
Sequence Planes Description
Scouts Sagittal, coronal, axial Localizer
Single-shot Fast spin echo Axial Provides overview of morphology
Balanced Steady State Free Precession (SSFP)- Single shot Axial Provides overview of morphology
Cine SSFP 2-chamber, 3-chamber, 4-chamber,
short-axis stacks











T1- mapping Short-axis stacks Tissue characterization
(fibros is, amyloid, deposition, iron)
T2- mapping Short-axis stacks Tissue characterizaton
(edema)
Short axis Iron quantification
Diffusion Localized to mass Tissue characterization
Dynamic first pass perfusion Short-axis stacks Ischemia/infarct/microvascular obstruction/masses
2 min post contrast T1-weighted IR GRE Short-axis stacks For myocarditis, microvascular obstruction and
masses
Delayed enhancement sequences 2-chamber, 3-chamber, 4-chamber,
short-axis stacks
Evaluation of scarring and fibrosis
MR angiography Coronal/sagittal/axial Vascular anatomy
3d-whole heart SSFP Axial/targeted to coronary arteries Coronary artery anatomy
Vascular anatomy
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To characterize cardiac masses, MRI is performed using
multiple tissue weightings (T1-w, T2-w, fat saturated se-
quences), diffusion, and various stages of contrast enhance-
ment (early, dynamic perfusion, delayed enhancement).
MRI features that suggest a benign or malignant lesion in-
clude margin, size, location, calcification, and pericardial
effusion. Based on these factors, MRI has shown to be ac-
curate in the prediction of lesion type (area under curve for
two observers, 0.88 and 0.92, with p values < 0.0003 for
agreement between the observers) [15]. Using long inver-
sion times (>500 milliseconds), a thrombus can be distin-
guished from a neoplasm, since only a thrombus stays dark
at this sequence. In addition, MRI also provides informa-
tion on the extent of the mass, including involvement of
adjacent structures. It also provides functional information,
such as ventricular and valvular function, particularly if
there is a valvular extension.
FDG-PET is also valuable in the evaluation of cardiac neo-
plasm. For evaluating cardiac mass, normal myocardial up-
take is suppressed by fasting for at least 6 hours. Since malig-
nant cells accumulate more glucose than normal cells do as a
result of predominant glycolytic catabolism, significant up-
take of F-18 FDG is indicative of malignant tissue. PET-CT
has been shown to have 100% sensitivity and 86% specificity
in differentiating benign from malignant cardiac tumours at
SUV cut-off of 3.5 and 94% sensitivity with 100% specificity
with SUV cut-off of 4.5. Benign tumours show only slight
FDG uptake (2.8 + 0.9 vs 9.5 + 4.0 in malignant lesions).
Extra-cardiac tumour manifestations may also be elucidated
by whole-body PET/CT [16]. However, the CT component of
Table 3 Advantages of PET, MRI, and PET/MRI in different cardiac applications
Indication PET MRI PET/MRI
Myocardial structure Limited due to spatial
resolution
Excellent due to good spatial
resolution and several sequences
MRI contributes to improved spatial
resolution
Ventricular and valvular function Limited Highly accurate ventricular function
Valvular function can be quantified
MRI component provides the ventricular
function







Artifacts can limit diagnosis Several solutions available for
artifacts
The MRI component can enable reducing
artifacts




Localization of abnormal FDG activity in
PET scan










Complementary information provided by
different mechanism
Morphological, functional, and metabolic
information
Vasculitis Metabolic activity Disease activity
Morphological information
Vascular anatomy, complications
Evaluation of disease activity
Comprehensive evaluation of vascular tree





MRI localizes activity of PET
Perfect spatial alignment
Evaluation of lumen with MRI
Lower radiation than PET/CT
Targeted isotopes localized with MRI
Myocardial ischemia Accurate
Absolute quantification of
MBF and CFT possible
Highly accurate
Can quantify ventricular function
Coronary anatomy can be evaluated
Comprehensive evaluation of perfusion along
with vascular anatomy and function
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PET is often inadequate to provide morphological informa-
tion, which is essential for pre-surgical evaluation.
Fig. 1 Characterization of mass. a 20-year-old female with irregular
heart rate noted on physical exam, which eventually led to a cardiac
MRI. Short-axis T2-weighted image shows intermediate to low signal
9 × 4 cmmass originating from the inferolateral basal to mid left ventricle
(arrow). b There was no immediate contrast enhancement (not shown
here), but there is intense delayed contrast enhancement in short-axis
inversion recovery sequence (arrow). c Four-chamber FDG-PET scan
shows no abnormal uptake in the mass, indicating a benign mass. The
imaging findings were thought to be suggestive of fibroma. Based upon
these findings, and the patient’s lack of symptoms, a choice was made to
not intervene, and instead to obtain clinical follow-up as well as serial
imaging. The patient has done well over six years, and the mass has
shown no interval change in size
Fig. 2 Characterization of mass. a Axial FDG-PET/CT scan in a patient
with known thyroid cancer showed intensely hypermetabolic lesion
(arrow) in the heart, which could not be localized clearly. b Four-
chamber delayed enhancement cardiac MRI shows the mass to be
entirely located within the left ventricular cavity. The mass has two
distinct components, an enhancing component (red arrow) and a non-
enhancing component (yellow arrow), which correspond to metastatic
lesion and superimposed and bland thrombus, respectively. The patient
was placed on anticoagulants in addition to chemotherapy
Fig. 3 Characterization of mass. a Contrast-enhanced 3d SSFP MR
image in a patient who presented with acute onset chest and back pain,
shows a non-enhancing mass located in the atrial septum and left atrium
extending to the mediastinum. b FDG-PET shows that there is no
significant tracer accumulation in the mass. Based on the imaging
findings, a neoplasm was excluded and a diagnosis of atrial hematoma
was made. Follow-up imaging (not shown here) showed improvement
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There are several scenarios in which the combination of
MRI and PET provides additive information. This includes
(1) the characterization of mass; (2) localization of abnormal
FDG activity seen in PET scan; (3) assessment of cardiac
involvement of mass seen in PET scan; (4) local staging, mor-
phological information, and aggressiveness; (5) M staging; (6)
functional evaluation; and (7) response to therapy,
distinguishing scar tissue from recurrence.
Characterization Although MRI and FDG-PET by them-
selves can characterize many tumours, the combination of both
improves the diagnostic confidence in distinguishing malignant
from benign lesions. If there is no FDG activity in a lesion, a
malignancy can be excluded in most cases—an important piece
of information that helps in management. False-positive FDG-
uptake can be seen in inadequate patient preparation, inflam-
matory conditions (e.g. sarcoidosis), infection, abscess, surgical
changes, radiation changes, and brown fat. Rarely, uptake can
be seen in myxoma, which is also a false-positive finding [17]
(Figs. 1, 2, 3 and 4). False-negative findings are seen in small
lesions and carcinoid. In addition, specific isotopes such as
18 F-FDOPA, 18 F-FDA (fluorodopamine), 11C-
hyroxyephedrine (11C-HED), and 68 Ga labelled may be use-
ful in the evaluation of paragangliomas.
Localization of abnormal activity seen in PET scan PET
scans performed for evaluation of tumours or other purposes
occasionally show abnormal focus of hypermetabolism in the
chest, either in or adjacent to the heart. It is often not possible
to accurately localize this lesion using PETor the correspond-
ing low-dose CT scan. In such situations, MRI can provide
additional information in localizing and characterizing these
masses [3, 15] (Figs. 5 and 6).
Assessment of cardiac involvement of mass seen in PET
scan Further to the above utility, occasionally there are masses
identified in PET imaging, which are in or adjacent to the heart
(Fig. 7). It is important to identify the extent of involvement of
the heart, particularly the involvement of cardiac chambers, myo-
cardium, or pericardium. Correlative MRI images will allow for
greater precision in cardiac mass anatomic localization [3].
Fig. 4 Characterization of mass. a Coronal first-pass perfusion MR
image in a patient who presented with chest pain and IVC mass on
echocardiography shows a mass that demonstrates contrast
enhancement similar to the liver parenchyma. The mass also showed
similar signal to liver in all other MRI sequences (not shown here). b
Coronal FDG-PET/CT image shows no uptake in the lesion, indicating it
is a benign process. This was proven to be a rare case of aberrant liver,
which extended into the IVC
Fig. 5 Localization of abnormal activity. a Axial FDG-PET/CT image
shows a focus of high uptake adjacent to the SVC, which extended
inferiorly. b Four-chamber SSFP MR image through the heart shows
lipomatous hypertrophy of the interatrial septum (arrows), with sparing
of fossa ovalis. This corresponds to the area of hypermetabolism in PET/
CT. Although a benign lesion, this can occasionally show uptake in FDG-
PET
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Evaluation of aggressiveness of lesion As discussed above,
morphological information on the extent of tumour and in-
volvement of adjacent structures is essential for surgical plan-
ning (Fig. 8). Neither PET nor the low-dose CT of PET/CT
routinely provide this information and MRI is well suited for
this purpose [3]. However, FDG-PET provides information on
distal spread throughout the body [16].
M staging Additional information obtained from PET can
help in identifying non-cardiac primary or secondary neoplas-
tic processes (Fig. 9). For example, paraganglioma is a tumour
that is most often benign, but can be malignant in 10 % of
cases. There are no specific imaging, or histological features
to distinguish a benign or malignant paraganglioma. The only
way to establish malignancy is to evaluate the presence of
distal spread. Using FDG-PET, this can be determined and
this helps in deciding the nature of the neoplasm (Fig. 10).
Probst et al. reported the beneficial use of PET/MR in a patient
with squamous cell carcinoma of lung with metastasis to the
cardiovascular system [18]. Recently, whole-body MR
Fig. 6 Localization of abnormal activity. a FDG-PET/CT image in a
patient with breast cancer shows intense uptake in the anterior
mediastinum abutting the heart. The exact location and extent of this
lesion is not evident. b Axial delayed enhancement image shows that
there is a heterogeneously enhancing mass in the right ventricle (arrow)
that is extending to the right ventricular apex and also invading the right
ventricular free wall
Fig. 7 Evaluation of cardiac infiltration. a FDG PET/CT in a patient with
lymphoma shows a focus of hypermetabolism adjacent to the SVC. The
exact extent of this is not evident in the PETor the concomitant low-dose
CT scan. b MRI was performed for evaluating cardiac extension. T1-
weighted axial image shows that the mass (thin arrow) has a clear fat
plane (thick arrow) with the SVC and cardiac structures, indicating that
it is not infiltrating the cardiac structures
Fig. 8 Local extension. a Axial FDG-PET/CT image in a patient with
melanoma shows multiple hypermetabolic nodules on the cardiac surface
(arrow). There is also pericardial effusion. bMRI was performed to better
characterize the extent of these lesion, particularly to see whether there
was myocardial involvement. Four-chamber delayed enhancement MRI
shows the multiple pericardial masses extending to the myocardium.
Diffuse heterogeneous myocardial enhancement (arrows) is seen,
indicating diffuse infiltration
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diffusion-weighted imaging has been used in oncology. This
technique has a high contrast between tumour and background
tissues and is used for detection of tumour (primary, recur-
rence, secondaries), tumour grading, and therapy monitoring,
particularly for bone metastases [19].
Functional information The MRI component also provides
valuable functional information such as the involvement of
crucial structures e.g., valve and papillary muscles. In
addition, accurate quantification of ventricular and valvular
function can be made.
Response to therapy Tumour response to therapy can also be
evaluated using the metabolic activity of lesions with PET.
PETandMRI are also useful in distinguishing scar tissue from
recurrence [20].
A recent study showed that while FDG-PET and MRI sep-
arately had a sensitivity of 100 % and specificity of 92 % in
determining cardiac malignancy, PET/MR achieved sensitiv-
ity and specificity of 100 % (Fig. 10) [21]. In summary, PET/
MRprovides valuable information on local and distant staging
Fig. 9 Staging. a Short-axis delayed enhancement MRI in a 72-year-old
patient shows a mass in the ventricular septum (arrow) that has peripheral
enhancement and central non-enhancement. b FDG-PET/CT image
shows intense uptake in the mass in the ventricular septum, indicating
that this is malignant. c Coronal FDG PET/CT image in the same patient
shows the septal lesion (thin arrow). In addition, there was also a
hypermetabolic right apical lung mass (thick arrow), consistent with
lung cancer. The septal lesion is a metastasis. There were also
metastatic lesions in the spine
Fig. 10 Characterization and staging. a 2-chamber STIR image obtained
as a part of FDG-PET/MRI examination in a patient with cardiac mass
shows a well-defined hyperintense mass adjacent to the left atrial
appendage (arrow). This mass also showed intense contrast
enhancement (not shown here). b The fused FDG- PET/MR image in
the coronal plane shows intense uptake in the mass (arrow) adjacent to the
left ventricle. This was shown to be a paraganglioma. The FDG-PETT
scan also ruled out any other metastatic lesions, indicating that the lesion
was benign.
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and also evaluates treatment response. With a hybrid PET/MR
technique, this information can be obtained in a single study.
Inflammatory disorders
The combination of PET and MRI is valuable in several in-
flammatory disorders, such as myocarditis, sarcoidosis, peri-
carditis, and valvar infections.
Myocarditis
Myocarditis is characterized by an inflammatory reaction of
the myocardium. The aetiology of myocarditis can be endog-
enous (toxins, autoimmune processes, etc.) or exogenous
(bacteria, viruses, fungal, or parasites) [22]. MRI and PET
provide complementary information for the assessment of
myocardial inflammatory processes, including myocarditis
[23]. MRI sequences used for myocarditis include the follow-
ing: (1) T2-weighted (T2-W) images, which showmyocardial
oedema, an important hallmark of reversible inflammatory
injury. Typically, myocardial oedema is seen locally, in a
non-vascular distribution in subepicardial or mid-myocardial
location. Occasionally, the oedema is diffuse and can only be
detected by quantification of the T2 value, particularly when it
is two standard deviations above that of skeletal muscle [24];
(2) early gadolinium enhancement, i.e. T1-weighted (T1-W)
fast-spin echo images taken 1–2 mins after the injection of
contrast agent, which shows enhancement in acute myocardi-
tis due to hyperemia and capillary leak; and (3) delayed en-
hanced images taken 10–15 minutes after the injection of con-
trast agent, which shows enhancement due to fibrosis and
necrosis [24–26], thus representing irreversible myocardial
injury. The overall sensitivity, specific, accuracy, positive pre-
dictive value, and negative predictive value of MRI for myo-
carditis is 59 %, 86 %, 68 %, 89 %, and 53 %, respectively
(24). On 18F-FDG PET scans, myocarditis presents as diffuse
increased metabolic activity with areas of heterogeneity.
Increased metabolic activity in myocarditis is secondary to
microvascular andmyocyte damage as well as changes in fatty
acid metabolism [23]. Increased metabolic activity in myocar-
dium is, however, nonspecific and can also be seen in conges-
tive heart failure, right ventricular strain, and hypertrophy due
to pulmonary hypertension [26].
The abnormalities in PET and MRI are based on differ-
ent mechanisms, and hence they may provide complemen-
tary information in myocarditis. Other than functional in-
formation on the myocardial activity from MRI, PET can
demonstrate activity of the inflammatory process in the
myocardium (Fig. 11). MRI also provides functional infor-
mation of the ventricles and valves. Since myocarditis usu-
ally affects younger patients in comparison to neoplastic
cardiac masses, an argument could be made for the use of
PET/MR as compared to PET/CT due to lower radiation
exposure. PET and MRI can also be used for assessment of
the response to medical treatment. However, other than
short case reports, there is still lack of published reports
on use of PET/MR in identification and follow-up of pa-
tients with myocarditis [27].
Sarcoidosis
Sarcoidosis is a systemic granulomatous disease of unknown
aetiology, likely due to an alteration in the immune response
after exposure to an environmental, occupational, or infectious
agent in genetically susceptible individuals [28]. Pathologic
hallmark of sarcoidosis is non-caseating granuloma [29]. On
MRI, acute phase of sarcoidosis manifests with myocardial
thickening and oedema. Patchy myocardial oedema is seen
due to active inflammation and is more commonly seen in
the subepicardial region and less commonly in the mid-
myocardial region. The oedema corresponds to areas of active
inflammation, may present with ventricular arrhythmia or
conduction disturbance, and usually responds to steroid ther-
apy [30]. In the chronic phase, there may be wall thinning.
Delayed enhancement is seen in up to 50 % of patients, in a
mid-myocardial or subepicardial distribution due to replace-
ment fibrosis [31]. Sarcoidosis often involves the septum (par-
ticularly basal portion) and left ventricular wall with rare in-
volvement of the right ventricle and papillary muscles [32].
Wall motion abnormalities are also seen.
Fig. 11 Myocarditis. a Short-axis delayed enhancement MRI in a patient
with acute onset chest pain and elevated enzymes shows mid-myocardial
enhancement in the mid lateral and inferior segments (arrow). b Fused
PET/MR image obtained after glucose diet shows patchy areas of intense
uptake in the lateral and inferior wall, indicative of active inflammation
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18F-FDG PET is also useful in the identification of cardiac
sarcoidosis, with a sensitivity and specificity of 89 % and
78 %, respectively [29]. Recently, published data support the
growing role of 18F-FDG PET-CT in the diagnosis, risk strat-
ification, and assessment of response to treatment of patients
with cardiac sarcoidosis [4].
With PET/MR, the MR component evaluates for active
inflammation, wall motion abnormalities, and fibrosis. FDG
uptake indicates inflammation (Fig. 12). Since the disease
detection is based on different mechanisms, the information
obtained may be complementary, resulting in possible
improved sensitivity in disease detection. PET/MRI also has
the advantage of providing valuable information on the exact
anatomical extension of sarcoidosis in the cardiovascular sys-
tem, functional assessment of the myocardium as well as
assessment of the disease activity and response to treatment
(Fig. 12). This can help to improve the selection of available
treatment options including medical management and cardiac
resynchronization therapy [33].
PET/MR is also useful in other inflammatory disorders, such
as Erdheim Chester disease (Fig. 13), which is a rare disorder
characterized by abnormal proliferation of non-Langerhans his-
tiocytes, resulting in fibrosis that affects multiple organs.
Pericarditis
Inflammation of the pericardium can have diverse aetiologies
including idiopathic, autoimmune diseases, infections, post
myocardial infarction, uremia, and radiation. Pericarditis can
be of acute, chronic inflammatory, or chronic fibrosing types.
MRI has become an important modality in the evaluation of
pericardial disease. In acute pericarditis, there is pericardial
thickening, pericardial effusion (Fig. 14a), and pericardial in-
flammation, which is manifested as delayed enhancement. In
the chronic phase, pericardial thickening is present, but with
lower amount of effusion and inflammation than acute type. In
chronic fibrosing type, there is pericardial thickening with/
without calcification and features of pericardial constriction
may be seen. MRI is valuable in the evaluation of pericardial
constriction, since it shows features of ventricular interdepen-
dence such as exaggerated septal flattening in real-time imag-
ing (Movie 1), diastolic septal bounce, and abrupt cessation of
diastolic filling. MRI is increasingly being used in the evalu-
ation of pericardial inflammation, particularly in the context of
transient pericardial constriction, which may be seen in the
acute or subacute phase of pericarditis due to impaired peri-
cardial distensibility. Although the standard treatment of peri-
cardial constriction is aggressive pericardial stripping, in tran-
sient pericardial constriction, anti-inflammatory therapy
(NSAIDs, colchicine, steroids) may be beneficial [34]. The
presence of inflammation on MRI, even in the absence of
clinical and serologic evidence of inflammation warrants con-
tinued therapy [34].
Inflammatory processes involving the pericardium demon-
strate amild-to-moderate FDG uptake (Fig. 14b), but occasion-
ally no FDG uptake can be seen. In contrast, markedly in-
creased FDG uptake is seen in proliferative neoplastic disor-
ders that often corresponds with a localized mass [32]. A pre-
liminary study showed that the FDG uptake is strong in tuber-
culous pericarditis compared to mild to moderate uptake in
idiopathic pericarditis. In addition, hypermetabolic lymph
nodes were also seen in tuberculous pericarditis [35]. Other
causes of pericarditis can be distinguished based on history
and FDG uptake patterns. Following surgery, there is diffuse
andmild uptake and following radiation, there is diffuse uptake
corresponding to the radiation port. Chemotherapy pericarditis
is homogeneous and diffuse. Chronic pericarditis shows thick-
ening and diffuse mild uptake with small or no effusion [35].
Fig. 12 Sarcoidosis. a 32-year-old male admitted after a syncopal
episode while shoveling snow. He was diagnosed with pulmonary
sarcoidosis by transbronchial biopsy. Four-chamber delayed
enhancement MRI shows patchy, diffuse areas of subepicardial as well
as transmural areas of delayed post-contrast enhancement involving both
ventricles (thin arrows). Bilateral hilar adenopathy was also seen (thick
arrows). b FDG- PET after a fatty diet shows patchy areas of high
uptake in the myocardium indicating areas of active inflammation
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Although most cases of pericarditis do not require PET/MR,
unique information provided by PET can be superimposed to
MRI or CT and thus help to improve identification of inflam-
matory processes or masses in uncertain cases, to exclude other
infectious foci, and aid in evaluation of response to therapy.
Cardiac valve abscess
Valve abscess is considered a complication of infective endo-
carditis (IE), either in a native or prosthetic valve, and requires
urgent surgery with debridement of all infected and necrotic
tissues. Echocardiography identifies only 40 % of surgically
proven myocardial abscesses [35]. On MRI, morphological
and functional evaluation of the valve can be performed along
with quantification of valvular lesions such as regurgitation or
stenosis. Inflammation or abscess is seen as soft tissue sur-
rounding the valve. Inflammatory tissue has high signal on
T2-weighted sequences (Fig. 15a) and abscesses show fluid
signal with peripheral enhancement.
PET-CT has been shown to have higher sensitivity than
echocardiography in the detection of valve abscess, showing
intense uptake in the affected valves (Fig. 15b) [7]. Hybrid
PET/MR imaging can aid in the characterization and loca-
lization of the high uptake zone on PET due to the excellent
spatial resolution capabilities of MRI. The tissue
characterization of MRI can also help to improve assessment
of post-surgical cases in which high uptake can be expected
due to post-surgical changes or residual/recurrent abscess.
Information obtained from hybrid PET/MR can also achieve
better differentiation of valve abscess from infective valve
vegetations. Although there are some case series on the diag-
nostic value of PET-CT [36], there is no published report on
the additional value of PET/MR in identification and manage-
ment of cardiac valve abscesses [36]. MR or PET/MRI in
patients with prosthetic valves can be challenging due to sus-
ceptibility artefacts. Sequences with lower susceptibility arte-
facts such as a conventional gradient-echo than a steady-state
free precession (SSFP) should be used.
Vascular disease
Vasculitis
Vasculitis is inflammation of the vascular wall and can be
classified based on the size of the affected vessels, location
of vessels, and underlying cause. Aetiologies for vasculitis
include autoimmune diseases, infection, and post chemother-
apy [37]. Signs and symptoms are primarily dependent on the
affected vessels and severity of disease. Although definitive
Fig. 13 Inflammatory disease. a 46-year-old male with history notable
for hypertension, bilateral orbital xanthogranulomas, and chronic low-
grade fevers. As part of work-up, the patient had an aortic MRI that
demonstrated diffuse confluent soft tissue within the mediastinum
(arrow). b There were additional soft tissue changes as well as
stranding surrounding both kidneys (arrows). c FDG PET/CT showed
only minimal FDG avidity in the paraaortic soft tissue. d FDG-PET/CT
also showed only minimally increased uptake around the kidneys. Bone
scan (not shown here) was notable for diffusely increased uptake along
long bones. Given these imaging and clinical findings, chronic
inflammatory process with suggestion of mild activity at time of
imaging was suspected; laboratory testing of orbital biopsy (CD68,
CD163 positive, CD1a negative) led to a diagnosis of Erdheim-Chester
disease
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diagnosis is established using biopsy, inflammatory markers
and imaging are also helpful in diagnosis.
On MRI, active large vessel vasculitis presents with wall
thickening, which may show oedema on STIR and enhance-
ment with contrast. The oedema seen on STIR images, how-
ever does not show a consistent relationship with disease ac-
tivity [38]. MR angiography provides comprehensive evalua-
tion of the vasculature, able to identify abnormalities such as
aneurysms and stenosis, and can be used to screen high-risk
patients without any radiation exposure. MRI has been shown
to have a sensitivity of 80 % and specificity of 90 % in the
diagnosis of giant cell arteritis [39]. Since 18F-FDG accumu-
lates in the macrophage-rich areas, vasculitis is seen in PET
with high uptake in the vascular wall in a linear pattern.
However, the tracer uptake for inflammatory disease is lower
than for oncologic disease [40]. Also, PET/CT lacks the capa-
bility to show the vessel wall in the low-dose non-contrast CT.
FDG-PET.CT has been shown to have an overall sensitivity
and specificity of 80% and 89% for the diagnosis of giant cell
arteritis when compared to reference clinical criteria [39].
PET/MR combines the anatomic information provided
with MRI with the metabolic activity of PET, providing a
reliable diagnosis of vasculitis with lower radiation dose than
PET/CT, also at the same time enabling assessment of aneu-
rysms and stenosis in the vasculature. In a pilot study on 14
consecutive examinations, PET/MR was found to be efficient
in the evaluation of large vessel vasculitis and that only a
combination of PET and MRI revealed the whole disease ex-
tent (Fig. 16). In MRI, abnormal segments were seen in 32/
149, and in FDG 78/149, for an overall number of 83/149.
Also, there was a strong and significant correlation between
CRP and the number of vessel segments affected by inflam-
mation in PET/MR (r=0.86, p=0.01) in contrast to PET or
MRI only. Thus, PET and MRI are complementary for di-
agnosis and likely to be more accurate to assess the true
extent of disease than either modality alone [41]. While
Fig. 14 Pericarditis. a Coronal FDG PET/CT in a patient showed intense
uptake in the pericardium. b Short-axis delayed enhancement MRI shows
diffuse circumferential delayed pericardial enhancement (arrows), which
is consistent with pericardial inflammation. There was also pericardial
thickening in black blood images (not shown here)
Fig. 15 Perivalvular abscess. a Three-chamber Cine SSFPMRI image in
a patient with history of bioprosthetic aortic valve replacement who
presented with acute onset chest pain shows a soft-tissue intensity
lesion surrounding the aortic valve and the aortic root (arrow). Contrast
was not administered due to severe renal dysfunction. b Coronal FDG
PET/CT in the same patient shows intense uptake along the lesion, which
indicates that this is active inflammation/infection. Follow up MRI
obtained two days later showed liquefaction and formation of abscess.
This was treated surgically
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the disease activity can be evaluated more accurately with
PET, MRA provides a comprehensive evaluation of the
vascular tree without the need for ionizing radiation [42].
Atherosclerotic disease
Atherosclerosis is a diffuse, chronic inflammatory disorder
characterized by deposition of lipid and fibrous products in
the vessel wall, following complex biological processes.
Current imaging techniques focuses on the detection of steno-
sis, grading of stenosis and evaluation of perfusion abnormal-
ities distal to the stenosis. However, major events such as
myocardial infarction (MI) and stroke are not produced by
plaques with associated stenosis, but by non-stenotic plaques
that get disrupted, the so-called vulnerable plaque. Hence, it is
vital to be able to detect, quantify, and characterize the biolog-
ical activity and stability of plaque at a subclinical stage.
Identification of these high-risk features along with plaque
burden will significantly help in the diagnosis and manage-
ment of these patients [43].
High-resolution multi-contrast imaging of the vessel wall
(T1-w, T2-w, PD, TOF) and dynamic contrast-enhanced angi-
ography can characterize the specific tissue components of
complex plaques, which helps to delineate biologic activity
(Table 4) [43]. High-risk features of an atherosclerotic plaque
include a large lipid-rich necrotic core, thin fibrous cap, endo-
thelial denudation with superficial platelet aggregation, fissured/
injured plaque and active inflammation. Stenosis>90 %, super-
ficial calcified nodule, intraplaque haemorrhage, outward posi-
tive remodelling and adventitial inflammation/neovascularity
are the other features of vulnerability. Flow can be evaluated
using time-of-flight sequence. Due to the smaller size, evalua-
tion of coronary arteries is challenging, but this technique has
been well established in the evaluation of carotid plaque [43].
FDG-PET has also been shown to be useful for assessment
of inflammatory activity within plaque since macrophages in
an inflamed plaque show avid FDG uptake and accumulation.
High uptake has been shown both in symptomatic and asymp-
tomatic plaques [44]. It has also been shown that there is a
correlation between FDG uptake and extent of macrophage
infiltration in a vulnerable carotid plaque [45]. However, low
spatial resolution of clinical PET machines limits identifica-
tion of small plaques and localization of high FDG uptake
zones.
With PET/MR, the high spatial resolution of MRI helps in
localizing the metabolic activity obtained from PET (Fig. 17)
Fig. 16 Vasculitis. a Axial STIRMRI image performed in a patient with
suspected vasculitis following lung cancer chemotherapy shows an
intense high signal in the wall of the ascending and descending aorta
(arrows), which is indicative of active vasculitis. b Sagittal FDG PET
image in the same patient shows the intense uptake along the wall of
the thoracic aorta (arrow). c This high uptake is localized better to the
aortic wall (arrow) using the fused PET/MR image (bottom)
Table 4 Characteristics of plaque
components in high-resolution
multi-contrast MRI
Component T1-w T2-w PD Contrast enhancement
Lipid High Intermediate Intermediate No
Fibrocellular High High High No
Calcium Low Low Low No
Necrotic core Low High High No
Fibrotic cap Low Low Low Yes
Haemorrhage High Low Intermediate No
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[46]. Simultaneous acquisition also results in perfect spatial
alignment. In addition, MRI also provides additional informa-
tion on plaque components as described above [43]. Thus, the
biological features of plaque obtained by PET provides addi-
tional information with multi-parametric plaque morphology
assessment with MRI. The lumen can also be assessed at the
same time for stenosis/occlusion. There is also potential for
using targeted PET isotopes, which hone in on specific mo-
lecular targets of atherosclerosis, such as macrophage, or re-
ceptors of angiogenesis, vascular adhesion, and apoptosis.
Some potential agents include 68 Ga-DOTATATE and
68 Ga- NOTA-RGD [46]. A recent study in HIV patients
found congruence between PET/MR and PET/CT SUV
values and improved delineation of outer and inner wall of
carotid artery from MRI [47, 48]. MRI can be used for mor-
phological follow-up and the combination can be used in drug
trials.
Coronary artery disease (CAD)
Myocardial ischemia
Myocardial ischemia occurs when the oxygen requirement of
part of myocardium exceeds the oxygen supply derived by
coronary arteries, typically caused by coronary atherosclerotic
disease. Identification of myocardial ischemia is essential in
patients with coronary artery disease for management and for
prognosis.
MRI is very useful in the evaluation of myocardial ische-
mia. Dynamic first-pass perfusion MRI performed at rest and
stress has been shown to have high accuracy in the evaluation
of myocardial ischemia. The CE-MARC trial showed sensi-
tivity (86.5 %) and negative predictive value (90.5 %) of MRI
to be statistically superior to that of SPECT (66.5 % and
79.1 %, respectively), while the specificity (83.4 % vs
82.6 %) and PPV (77.2 % vs 71.4 %) were non-statistically
significantly superior [49]. Myocardial ischemia is seen as a
hypointense perfusion defect at first pass perfusion imaging
only at stress, with normal perfusion at rest.
Rubidium-82, Nitrogen-13 ammonia and 15 O labelled
water are the PET isotopes used for perfusion imaging. PET
has high accuracy, with sensitivity and specificity of 90 % in
detection of obstructive coronary disease [50]. In addition,
PET imaging is also valuable in quantification of myocardial
blood flow (MBF) and coronary flow reserve (CFR), which is
useful in multi-vessel disease, early changes of vasoreactivity
and follow-up [9]. Also, PET findings have prognostic value
[51].
With an integrated PET/MR system, simultaneous 13 N
ammonia PET-MR myocardial perfusion has the advantage
of increasing the accuracy of MR perfusion by the PET com-
ponent, since the N-13 ammonia perfusion imaging has more
coverage than stress perfusion MR. 13 N-ammonia PET has
been shown to be an important cost-effective strategy in clin-
ical decisionmaking [52]. UtilizingMR attenuation correction
data eliminates the radiation associated with CT attenuation
data. Also, the examination time is shortened, since rest-phase
13 N-ammonia images are not required and are replaced by
delayed enhancement images. In addition, MRI can also help
address artefacts caused by motion or partial volume averag-
ing. Ventricular function, global and regional, can be evaluat-
ed in the same study. A study which comparedMRI with PET
showed high accuracy of MRI in evaluating pathology with
sensitivity of 91 % and specificity of 94 % compared to PET
scan, but with significant underestimation of CFR [53].
Challenges of perfusion PET include lack of a good flow
tracer for PET MPI, and short half-life of the isotopes, which
necessitates having a cyclotron on site.
Myocardial infarction
Myocardial infarction results from death of myocardial tissue
due to blockage of coronary arteries. Imaging is useful in the
diagnosis, prognosis, and evaluation of complications. An im-
portant contribution of imaging is detection of viable myocar-
dium, which is dysfunctional but not dead, and hence can
recover its function following revascularization.
Delayed enhancement imaging is highly sensitive and spe-
cific in the evaluation of myocardial infarct, both in acute
(sensitivity of 99 %) and chronic phase (sensitivity 94 %)
[53]. MI is manifest as a subendocardial or transmural pattern
Fig. 17 Carotid atherosclerosis. a Axial proton density-weighted MRI
image (top) shows mild thickening of the wall of the left carotid artery
(arrow) due to a plaque. b Axial fused PET/MR image at the same level
shows uptake in the same area (arrow), indicative of plaque inflammation
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of enhancement confined to a vascular territorial distribution
[54]. MRI is accurate in the quantification of myocardial func-
tion and scar, which has prognostic value. Dysfunctional seg-
ments with scarring>50% of myocardial thickness have been
shown to have lower probability of functional recovery after
revascularization [55]. MRI can also evaluate several compli-
cations of MI including thrombus, rupture, ventricular septal
defect, pericarditis, etc.MRI has prognostic value and can also
provide functional information [56]. The difference between
oedema seen in T2-weighted images and the scar seen in de-
layed enhancement is considered the salvageable area by
myocardial reperfusion [57].
PET is also very reliable in the evaluation of myocardial
viability, quantifying the degree of viability [58]. With PET,
myocardial viability is detected by using a combination of
perfusion imaging and FDG study [58]. Infarcted scarred tis-
sue does not have 18F-FDG uptake (Fig. 18), while a viable
hibernating myocardium has 18F-FDG uptake (Fig. 19).
Hence, a matched defect, i.e. a defect in perfusion imaging
Fig. 18 Myocardial infarction. a Short-axis delayed enhancement MRI
in a patient with myocardial infarction shows a large transmural scar of
the anterior wall (yellow arrow) and partial thickness scarring of the
inferolateral segment (red arrow). Viability of this segment is
borderline. b Fused PET/MR image shows no uptake in the anterior as
well as inferolateral segments, indicating that these are not viable. Thus,
the combination of these imaging modalities improves the diagnostic
confidence
Fig. 19 Hibernating myocardium. a 57-year-old male with coronary
artery disease, status post multiple prior percutaneous interventions,
with symptoms of angina at rest. Short-axis delayed enhancement MRI
shows partial thickness scar in the anterolateral segment (yellow arrow)
and near-full thickness scar in inferolateral segment (red arrow). b Rb-82
PET rest perfusion image shows perfusion defect in the anterolateral and
inferolateral segments (yellow and red arrows, respectively). This was
similar on stress images as well. c FDG-PET image shows no uptake in
the inferolateral segment (red arrow) indicating non viability, while there
is uptake in the anterolateral segment (yellow arrow), indicating
hibernating myocardium
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and FDG scan, is indicative of a scar, while a mismatched
defect, i.e. a defect in perfusion imaging, but normal FDG
uptake, is indicative of hibernating myocardium [59].
A study using FDG and 13NH3 PETandMRI showed that
MRI can depict areas of non-transmural enhancement in via-
ble areas of PET due to higher spatial resolution [60]. There
was good correlation between the modalities for location and
extent of infarct. Both modalities have comparable PPV for
functional recovery after revascularization using 50 % thick-
ness enhancement and 50% FDG activity as cut off [58]. Both
these techniques have high sensitivity but low specificity
(63 %) in predicting functional recovery after revasculariza-
tion, indicating that segments called viable do not always im-
prove [61].
PET-MRI can also evaluate and characterize the heteroge-
neity of the scar tissue, since this is a marker for inducible
monomorphic ventricular tachycardia [53]. The combination
of PET SUV maps, metabolic function, delayed enhancement
and T1 mapping may be better predictor of arrhythmia sus-
ceptibility than MR alone. The combination of PET and MRI
can also assess other features such as decreased wall thicken-
ing, regional functionional abnormalities, lack of contractile
response to low-dose dobutamine, preserved sub-epicardial
myocardium, and preserved perfusion [9]. Both modalities
provide prognostic information, although FDG-PET depends
on mismatch between flow and glucose uptake, and MRI de-
pends on infarct size.
Ventricular function
Cardiac MRI is considered the gold standard in evaluation of
myocardial function [60]. PET scan has significantly lower
spatial and temporal resolution thanMRI, limiting its accuracy
in evaluation of cardiac function. Left ventricular function is
calculated by algorithm-dependent assumptions on endocar-
dial and epicardial border. Hence, the MRI component of
PET/MR provides more accurate quantification of ventricular
function.
Coronary angiography
MRI also provides morphological information on the coro-
nary arterial anatomy, including luminal stenosis [62].
Although inferior to CT, MRI can also be used for the
evaluation of the anatomy of coronary arteries and evaluate
coronary artery disease, with reasonably good accuracy. A
recent multicenter trial showed sensitivity of 88 %, specificity
of 72%, PPVof 71%, and NPVof 79% compared to coronary
angiography [62]. MR coronary angiography is performed
using a 3d- SSFP sequence with navigator gating, images
acquired during end-expiration and in diastole, with myocar-
dial suppression by T2 prepared sequence. Thus, MRI pro-
vides concomitant anatomic information.
Emerging and future applications
There are several emerging potential areas where hybrid PET/
MRI is valuable in cardiovascular disorders. The most impor-
tant application would be to utilize the high spatial resolution
of MRI to localize the uptake of novel PET isotopes that are
targeted towards specific pathophysiological process. This
combines the anatomical detail of MRI with the highly sensi-
tive metabolic information of PET. For example, 11C-labelled
metahydroxyephedtrine (HED) and β-adrenoreceptor tracers
can image defects of sympathetic innervation in cardiac disor-
ders such as CAD, heart failure, and arrhythmias, thus helping
in diagnosis, prognosis and selecting the appropriate therapy.
19 F- galacto RGE enables imaging of αvβ3 integrin, which is
a marker of angiogenesis and also accumulates in the injured
myocardium and thus can monitor effectiveness of therapies
that aim to heal myocardium. Stem cell therapy can be directly
visualized by reporter gene PET imaging [9].
Conclusion
MRI and PET are clinically established imaging modalities,
with complementary strengths which can be invaluable in the
evaluation of a range of cardiovascular disorders. A combina-
tion of PET and MRI can provide synergistic information in
several scenarios for the enhanced characterization of cardio-
vascular disorders.With use of hybrid PET/MRI scanners, this
information can be obtained in a single scan.
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